Msefsl

CLOSE X

Risk Disclosures on Derivatives

>9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
>On an average, loss makers registered net trading loss close to ₹ 50,000.
>Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
>Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.

ALKEM LABORATORIES LTD.

NSE : ALKEMBSE : 539523ISIN CODE : INE540L01014Industry : Pharmaceuticals & DrugsHouse : Private

BSE5360.007.45 (+0.14 %)

PREV CLOSE ( ) 5352.55

OPEN PRICE ( ) 5352.55

BID PRICE (QTY) 5358.50 (1)

OFFER PRICE (QTY) 5362.50 (3)

VOLUME 53830

TODAY'S LOW / HIGH ( )5352.55 5469.60

52 WK LOW / HIGH ( )4716.75 5933

NSE5371.0015.5 (+0.29 %)

PREV CLOSE( ) 5355.50

OPEN PRICE ( ) 5355.00

BID PRICE (QTY) 5373.00 (2)

OFFER PRICE (QTY) 5374.50 (7)

VOLUME 71170

TODAY'S LOW / HIGH( ) 5345.00 5470.00

52 WK LOW / HIGH ( )4716.2 5933.5

BSE NSE

1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 08-08 1973

Management Info

Basudeo N Singh - Chairman Sandeep Singh - Managing Director

Registered Office

Address Alkem House,Senapati Bapat Marg,Lower Parel (West),
Mumbai,
Maharashtra-400013

Phone 022 3982 9999

Email investors@alkem.com / contact@alkem.com

Website www.alkemlabs.com

Registrars Details

MUFG Intime India Pvt Ltd.

C 101, 247 Park,LBS Marg,Vikhroli (West),Mumbai

Listing : BSE, NSE

NEWS

03Jun Alkem Laboratories launches semaglutid
Alkem Laboratories has launched semaglutide in single-shot pre-filled sy..

29May Alkem Laboratories informs about compl
Alkem Laboratories has informed that it enclosed the Annual Secretarial..

28May Alkem Laboratories reports 23% fall in
Alkem Laboratories has reported results for the fourth quarter (Q4FY26)..

20May Alkem Laboratories informs about conf
With reference to relevant provisions of SEBI (Listing Obligations and D..

09May USFDA completes inspection at Alkem La
The United States Food and Drug Administration (USFDA) has completed an..

Financials

Rs. in Millions

	QTR Mar 26	ANNUAL 26
Net Profit	2170.6	22820.9
Gross Profit	3360.9	25226.2
Operating Profit	5497.1	29795.6
Net Sales	22584.4	96639.1

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Abbott India (BSE) 26354.85 (0.80%)	M.Cap ( in Cr)56242.44
Kwality Pharma (BSE) 2493.75 (6.74%)	M.Cap ( in Cr)2651.12
Caplin Point Lab (BSE) 2348.35 (4.02%)	M.Cap ( in Cr)17988.55
Venus Remedies (BSE) 1682.35 (5.00%)	M.Cap ( in Cr)2248.80
Concord Biotech (BSE) 1336.50 (5.11%)	M.Cap ( in Cr)14049.43

Shareholding Pattern

	PROMOTERS	51.2%
	NON-INSTITUTION	17.25%
	MUTUAL FUNDS/UTI	15.57%
	FI/BANKS/INSURANCE	4.18%
	GOVERNMENT	0%
	FII	0%

Mf Holdings

Scheme Name	Hold(%)
Tata Nifty MidSmall...	4.49
Motilal Oswal Nifty...	4.47
ICICI Pru Pharma He...	4.01
NJ ELSS Tax Saver S...	3.58
LIC MF Healthcare F...	3.50
ICICI Pru Nifty Pha...	3.36
Nippon India Nifty ...	3.36

Risk Disclosures on Derivatives

Smart Quotes

ALKEM LABORATORIES LTD.